1800-272-662
Shopping Cart 0
countryflagAU
Login

Fisher & Paykel Healthcare Corporation Ltd

Healthcare AU FPH

31.87AUD
-0.01(0.03%)

Last update at 2026-03-12T05:45:00Z

Day Range

31.4632.11
LowHigh

52 Week Range

28.7535.13
LowHigh

Fundamentals

  • Previous Close 31.88
  • Market Cap20131.37M
  • Volume484768
  • P/E Ratio55.29
  • Dividend Yield1.26%
  • EBITDA696.70M
  • Revenue TTM2158.30M
  • Revenue Per Share TTM3.68
  • Gross Profit TTM 1367.90M
  • Diluted EPS TTM0.62

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Income before tax 503.30M 235.70M 328.00M 504.20M 718.20M
Minority interest - - - - -
Net income 377.20M 132.60M 250.30M 376.90M 524.20M
Selling general administrative 534.40M 492.80M 431.90M 393.10M 396.60M
Selling and marketing expenses 534.40M 492.80M 431.90M 393.10M 396.60M
Gross profit 530.20M 1044.40M 945.90M 1013.40M 1222.60M
Reconciled depreciation 139.90M 114.30M 99.00M 96.00M 85.00M
Ebit 514.40M 353.40M 334.70M 509.10M 723.20M
Ebitda 654.30M 444.80M 433.70M 605.10M 808.20M
Depreciation and amortization 139.90M 91.40M 99.00M 96.00M 85.00M
Non operating income net other - - - - -
Operating income -371.00000M 353.40M 310.80M 468.28M 654.80M
Other operating expenses 1651.30M 1389.40M 34.05M 76.69M 185.42M
Interest expense 11.10M 18.20M 6.70M 4.90M 5.00M
Tax provision 126.10M 103.10M 77.70M 127.30M 194.00M
Interest income 4.30M 3.30M 2.60M 2.60M 1.50M
Net interest income -6.80000M -14.90000M -4.10000M -2.30000M -3.50000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 126.10M 103.10M 77.70M 127.30M 194.00M
Total revenue 1280.30M 1742.80M 1588.60M 1642.40M 1948.20M
Total operating expenses 901.20M 691.00M 705.20M 643.10M 618.30M
Cost of revenue 750.10M 698.40M 642.70M 629.00M 725.60M
Total other income expense net 874.30M -117.70000M -7.60000M 40.20M 32.40M
Discontinued operations - - - - -
Net income from continuing ops 377.20M 132.60M 250.30M 376.90M 524.20M
Net income applicable to common shares - - 250.30M 376.90M 524.20M
Preferred stock and other adjustments - - - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 2550.80M 2281.70M 2204.50M 2107.00M 2075.00M
Intangible assets 82.10M 88.40M 85.60M 86.80M 80.00M
Earning assets - - - - -
Other current assets - 45.30M 68.90M 64.70M 49.30M
Total liab 660.40M 522.60M 451.10M 427.30M 554.10M
Total stockholder equity 1890.40M 1759.10M 1753.40M 1679.70M 1520.90M
Deferred long term liab - - - - -
Other current liab - 256.40M 230.90M 231.64M 340.87M
Common stock - 404.00M 303.70M 261.20M 249.10M
Capital stock 468.60M 404.00M 303.70M 261.20M 249.10M
Retained earnings 1226.60M 1095.00M 1200.50M 1181.20M 1029.20M
Other liab - - 36.80M 36.10M 33.90M
Good will - - - - -
Other assets - - 196.20M 174.40M 192.90M
Cash 264.50M 82.00M 121.00M 89.90M 97.30M
Cash and equivalents - - - - -
Total current liabilities 500.40M 385.00M 289.80M 303.90M 427.50M
Current deferred revenue - - -5.40032M 1.46M 3.33M
Net debt - 107.10M 24.80M 14.40M 21.10M
Short term debt - 96.20M 21.30M 17.00M 26.60M
Short long term debt 64.00M 78.50M 4.20M 5.30M 11.90M
Short long term debt total - 189.10M 145.80M 104.30M 118.40M
Other stockholder equity - - -1407.29444M -1335.92953M -1175.11483M
Property plant equipment - - 1148.20M 957.80M 882.10M
Total current assets 935.40M 704.90M 774.20M 887.90M 920.00M
Long term investments - - - - -
Net tangible assets - - 1667.80M 1592.90M 1440.90M
Short term investments - - 0.47M 200.00M 280.30M
Net receivables 267.30M 257.20M 218.50M 174.40M 222.50M
Long term debt - 35.70M 79.10M 63.00M 62.80M
Inventory 342.90M 320.40M 365.80M 358.90M 270.60M
Accounts payable 52.90M 32.40M 43.00M 53.80M 56.70M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 260.10M 249.20M 237.30M 242.60M
Additional paid in capital - - - - -
Common stock total equity - - - - 249.10M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -2.20000M
Accumulated amortization - - - - -
Non currrent assets other - 55.90M 99.62M 90.81M 134.23M
Deferred long term asset charges - - - - -
Non current assets total 1615.40M 1576.80M 1430.30M 1219.10M 1155.00M
Capital lease obligations 89.30M 74.90M 62.50M 36.00M 43.70M
Long term debt total - - - - 91.80M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Investments -103.00000M -339.00000M -11.30000M 80.30M -202.60000M
Change to liabilities - - -19.00000M -5.70000M 65.70M
Total cashflows from investing activities -103.00000M -339.00000M -11.30000M -89.50000M -387.30000M
Net borrowings -56.90000M 30.60M -4.40000M -14.10000M -10.20000M
Total cash from financing activities -268.20000M -128.70000M -197.10000M -235.80000M -188.00000M
Change to operating activities - - - - -
Net income 377.20M 132.60M 234.17M 349.08M 481.89M
Change in cash 179.30M -35.90000M 32.20M -0.80000M 49.00M
Begin period cash flow 80.90M 116.80M 84.60M 85.40M 36.40M
End period cash flow 260.20M 80.90M 116.80M 84.60M 85.40M
Total cash from operating activities 548.60M 429.60M 222.85M 300.36M 574.83M
Issuance of capital stock 3.10M 3.00M 3.00M 3.20M 3.50M
Depreciation - 109.10M 87.85M 80.30M 74.00M
Other cashflows from investing activities -29.40000M -22.20000M - - -202.60000M
Dividends paid -195.90000M -145.50000M -195.70000M -224.90000M -181.30000M
Change to inventory -22.50000M 45.40M -6.45548M -81.78215M -114.08257M
Change to account receivables -45.10000M -38.50000M -40.51047M 48.62M -4.68832M
Sale purchase of stock - - 137.50M 7.50M 45.30M
Other cashflows from financing activities -18.50000M -16.80000M -14.40000M -14.00000M -10.20000M
Change to netincome - - -41.90000M -107.10000M 79.60M
Capital expenditures 103.00M 339.00M 211.30M 169.80M 184.70M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -67.60000M 6.90M -46.96595M -33.15743M -118.77089M
Stock based compensation - 10.80M 8.42M 7.50M 7.08M
Other non cash items 616.20M 170.20M -99.17113M -129.01760M 18.94M
Free cash flow 445.60M 90.60M 11.55M 130.56M 390.13M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
FPH
Fisher & Paykel Healthcare Corporation Ltd		 -0.01 0.03% 31.87 55.29 45.45 9.33 12.10 16.65 32.34
RMD
Resmed Inc		 -1.07 3.13% 33.14 25.80 21.88 9.89 5.95 6.86 17.74
ANN
Ansell Ltd		 0.01 0.03% 29.80 23.37 19.46 2.20 1.64 1.90 12.60
NAN
Nanosonics Ltd		 -0.09 2.50% 3.51 49.00 46.30 5.02 4.47 4.00 26.19
SDI
SDI Ltd		 -0.005 0.40% 1.25 12.65 5.06 1.35 1.45 1.45 7.89

Reports Covered

Stock Research & News

View All

Profile

Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. It provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company also offers adult respiratory products, including airvo system, optiflow nasal high flow therapy, invasive ventilation, and noninvasive ventilation. In addition, it provides infant respiratory products, such as resuscitation, invasive ventilation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy products. Further, the company offers hospital products comprising humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, software and data management products, and humidifiers. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.

Fisher & Paykel Healthcare Corporation Ltd

15 Maurice Paykel Place, Auckland, New Zealand, 2013

Key Executives

Name Title Year Born
Mr. Lewis G. Gradon MD, CEO & Exec. Director 1961
Ms. Lyndal York Chief Financial Officer NA
Dr. Andrew Somervell VP of Products & Technology NA
Hayden Brown Investor Relations Mang. NA
Karen Knott Gen. Mang. of Corp. Communications NA
Mr. Paul N. Shearer B.Com. Sr. VP of Sales & Marketing NA
Ms. Nicola Talbot VP of HR NA
Mr. Jonathan Rhodes VP of Supply Chain, Facilities & Sustainability NA
Mr. Marcus Driller VP of Corp. & Company Sec. NA
Chris Crone Gen. Mang. of Airvo Optiflow NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.